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Retinopathy of prematurity (ROP) is a serious disease of premature 
infants that can lead to blindness. In 1995 it accounted for 10.6% of 
blindness in children in schools for the blind in South Africa.1 ROP 
is also associated with additional serious ocular complications such 
as an increased incidence of refractive errors, amblyopia, strabismus, 
cataracts and glaucoma.2 Screening and early intervention are 
essential to reduce the complications of ROP.
ROP has been identified by the World Health Organization as 
a priority eye disease in the Vision 2020 statement for the global 
initiative for the elimination of avoidable blindness.3 The prevalence 
of ROP is strongly influenced by the level of socio-economic 
development of a specific region. In low-income countries with an 
infant mortality rate (IMR) over 60/1 000, the babies at highest risk 
of ROP do not survive and these countries therefore have a relatively 
low incidence of the disease. In countries with a low IMR (<9/1 000), 
more babies at the borders of viability survive and the ROP incidence 
is therefore high, but because of extensive screening programmes the 
associated complication rate is low.4 South Africa (SA) is classified as 
a middle-income country and has an IMR of 42.7/1 000.5 This results 
in more babies surviving, but with a higher risk of developing ROP 
and its complications. Owing to financial constraints, physiological 
monitoring of sick infants is not optimal and the capacity for 
comprehensive screening programmes does not exist.
The most recent study on the incidence of ROP at our institution, 
Tygerberg Children’s Hospital (TCH), Parow, Cape Town, was 
undertaken in 1995. Among infants ventilated for respiratory distress 
syndrome (RDS), the prevalence of ROP was 31.1% and that of 
clinically significant ROP (CSROP) 7.1%.6 In the present study we 
differentiate CSROP (ROP of any grade in an area of the retina that 
might threaten sight) from ‘any ROP’, as the clinical implications differ.
Since 1995, protocols for treating infants with RDS have changed 
significantly. Surfactant has been introduced and use of non-invasive 
ventilation techniques has increased.
We aimed to determine the current prevalence of ROP at 
TCH in a cohort of preterm infants treated exclusively with 
non-invasive ventilation in the first week of life. Our second 
aim was to identify statistically significant risk factors for the 
development of ROP.
Methods
This study was a retrospective review of medical records of infants 
screened for ROP from January 2009 to December 2010.
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Objectives. To determine the current prevalence of retinopathy of prematurity (ROP) in premature babies treated with non-invasive 
ventilation at Tygerberg Children’s Hospital, Parow, Cape Town, South Africa, and to identify risk factors associated with the development 
of ROP.
Methods. A retrospective medical records review of infants screened for ROP during a 2-year period (January 2009 - December 2010). 
Infants who did not receive invasive ventilation during the first week of life were included. Twenty-four previously reported risk factors for 
the development of ROP were identified for use in a multivariate logistic regression (MLR) analysis.
Results. A total of 356 patients were included. The overall prevalence of ROP was 21.8% and that of clinically significant ROP (CSROP) 
4.4%. The risk factors with a statistically significant association with the development of ROP on MLR analysis were severe apnoea 
(p=0.0005) and decreasing birth weight (p=0.0382).
Conclusions. There is a low prevalence of ROP in the cohort of preterm infants treated exclusively with non-invasive ventilation in the first 
week of life. The risk factors of importance in our population were severe apnoea and lower birth weight. Birth weight is a practical and 
reproducible variable that can be used to aid development of ROP screening criteria.
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Inclusion criteria
Inclusion criteria were: (i) infants of ≤28 
weeks’ gestational age (GA) or ≤1 000 g birth 
weight (BW) (where there was a discrepancy, 
the lower value of either BW or GA was 
used); and (ii) premature infants >28 weeks’ 
GA or >1  000 g who had an exceptionally 
unstable course as per the discretion of the 
consultant.
Exclusion criteria
Exclusion criteria were: (i) invasive 
mechanical ventilation in the first week of 
life; (ii) major congenital abnormalities; and 
(iii) BW <500 g.
Medical management
In premature babies with any respiratory 
distress, continuous positive airway 
pressure ventilation (CPAP) was initiated 
immediately after birth by NeopuffTM, 
followed by nasal CPAP after arrival in 
the ward. A positive end-expiratory 
pressure (PEEP) of 4 - 5 cm H2O was used. 
Intubation, surfactant administration, then 
extubation (INSURE) was administered to 
infants with RDS (requiring a fraction of 
inspired oxygen (FiO2) ≥0.35 to maintain 
saturations between 86% and 92% after 1 - 4 
hours after birth). 
Failure of CPAP and indications for 
mechanical ventilation were defined as: 
(i) recurrent apnoea despite CPAP with 
adequate seal and PEEP; (ii) severe rib 
retraction, sternal recession or grunting 
indicative of unsustainable increased 
work of breathing; and (iii) oxygenation 
or ventilation failure, as defined by pulse 
oximetry saturations <90% or arterial 
oxygen level (PaO2) <7 kPa on FiO2 ≥0.6, 
arterial carbon dioxide level (PaCO2) 
>7.5kPa and pH <7.25 (or base excess 
>-10), or an alveolar-arterial ratio of 
oxygen <0.22.
Criteria for weaning off oxygen to 
minimise the risk of developing ROP were 
as follows: (i) 33 - 36 weeks’ corrected GA 
(or ≥1 500 g): maintain saturations at 
88 - 92%; and (ii) ≤32 weeks’ corrected 
GA (or <1 500 g): maintain saturations at 
86 - 90% (where there was a discrepancy, 
the lower value of either BW or GA was 
used).
Examination and staging of infants 
were done according to the International 
Classification of Retinopathy of 
Prematurity (2005 revision)7 by a 
paediatric ophthalmologist using a 
28-dioptre condensing lens and an indirect 
ophthalmoscope. A scleral depressor was 
used to rotate the globe in order to view the 
peripheral retina. Babies were examined 
from 31 weeks’ corrected GA and then 
1 - 3 times weekly until vascularisation of 
zone 3 was completed or the corrected GA 
of 41 weeks was reached. Babies who were 
not brought back for ROP screening were 
recorded as lost to follow-up.
CSROP was defined as ROP involving zone 
1, any stage 3 ROP, two or more quadrants 
of plus disease or worse surrounding the 
optic disc, or two or more quadrants of 
peripheral plus disease. Fig. 1 illustrates 
stages and zones, and Fig. 2 is an example 
of plus disease, showing a significant level of 
vascular dilation and tortuosity involving the 
posterior retinal vessels. Several risk factors 
have previously been found to be associated 
with development of ROP. The factors that 
we studied and their clarification are set out 
in Table 1.
Statistics
The clinical characteristics of the infants 
were described as either mean values with 
standard deviations (SDs), or rates and 
percentages. These characteristics were also 
described within weight subgroups. Two 
outcome measures were used, namely the 
presence or absence of any ROP and the 
presence or absence of CSROP. In order to 
determine which factors were associated 
with the outcome measures, univariate 
logistic regression analysis was performed to 
determine an association between the outcome 
measures and both continuous and categorical 
risk factors. Unadjusted odds ratios and 95% 
confidence intervals were also determined for 
each effect. A p-value of <0.05 was considered 
statistically significant. Variables found to be 
significant in the univariate analysis, as well as 
variables with known clinical relevance, were 
included as factors in a multivariate logistic 
regression (MLR). The MLRs were performed 
for each outcome in order to determine the 
possible association between the previously 
defined outcomes and the aforementioned 
variables. An adjustment was made for possible 
confounding of other factors.
Results
Of the 395 babies screened for ROP, 356 
were included in the study (Fig. 3). The 
population characteristics are shown in 
Table 2. The mean GA was 28.3 (SD ±1.7) 
weeks and the mean birth weight 949.3 g. 
Two hundred and twenty-nine infants 
weighed <1 000 g and 172 weighed ≥1 000 g. 
Only 1 infant who qualified for screening as 
per consultant discretion weighed ≥1 500 g 
– this baby weighed 1  560 g at 30 weeks’ 
GA and had a 36-day stay in the neonatal 
intensive care unit.
The prevalence of ROP (any ROP) was 
75/356 (21.8%) and that of CSROP 15/356 
(4.4%) (Table 3). There was no CSROP in 
the group that weighed more than 1 250 g 
at birth. Most ROP (75%) occurred in the 
weight category less than 1 000 g. Univariate 
Fig. 2. Plus disease (a signifi cant level of vascular 
dilation and tortuosity observed at the posterior 
retinal vessels).
Fig. 1. ROP stages (International Committee for the Classifi cation of Retinopathy of Prematurity 
classification) and zones.
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analysis of CSROP versus all babies without CSROP (Table 4) showed 
that the babies with CSROP were also significantly less mature (27.3 
v. 28.3 weeks’ GA) and smaller (851 g v. 949 g). A significantly greater 
number of babies with CSROP had severe apnoea (66.7% v. 26.5%) 
and hyperglycaemia (73.3% v. 44.2%), and received TPN (46.7% v. 
13.1%). Babies with CSROP had worse weight gain than infants who 
were not diagnosed with CSROP (53.3% v. 26.2%). HIV exposure was 
not associated with an increased prevalence of ROP.
MLR analysis revealed that lower birth weight and severe 
apnoea were the only statistically significant risk factors 
associated with the development of ROP (Table 5). Female 
gender showed a trend (p=0.07) towards having a higher 
prevalence of ROP. MLR analysis of CSROP versus no ROP and 
insignificant ROP was statistically not possible owing to the 
small numbers in the CSROP group.
Laser therapy was performed in 6 infants (1.5%). ROP screening 
was completed in 86.2%. The lost-to-follow-up rate was therefore 
13.8%.
Discussion
TCH is a tertiary hospital undertaking 6 000 complicated deliveries 
per year, drawn from the referral area in which there are 50 000 
deliveries per year.
The prevalence of ROP (21.8%) and CSROP (4.4%) among infants 
treated with non-invasive ventilation is low when compared with the 
results of Gilbert et al.8 It must be noted that these authors included 
ventilated babies, who are known to be at higher risk of developing 
ROP.
Varughese et al. found rates of ROP needing treatment of 1.6 - 2.9%.1 
They used a convenience sample that included 17 units from three SA 
provinces. In line with their findings, a 2006 study from Chris Hani 
Baragwanath Hospital reported a 16.3% incidence of ROP (adjusted 
estimation of CSROP 2.9%),9 while researchers from Kalafong Hospital 
(2002) reported an incidence of ROP of 24.5% (CSROP 4.3%).10 The 
neonatal unit at Groote Schuur Hospital (1991) reported an incidence 
of ROP of 19.2% (CSROP 1.56%).11 The abovementioned studies all 
included infants weighing <1 500 g.
Table 1. Risk factors for ROP included in the study
Risk factor Comments
Advancing maternal age
Maternal PET/PIH or chronic 
hypertension
Systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg ± >0.3 g protein in a 24-hour urine specimen, noted in 
pregnancy of >20 weeks’ gestation
Maternal DM Gestational or other types of DM in pregnancy
Antenatal steroids Any type or dose of steroid
HIV-exposed
Birth weight
Gestational age Calculated using one of the following: sure dates, early ultrasound (24 weeks was the cut-off for early 
ultrasound examination), late ultrasound, or the postnatally determined Ballard score15
Small for gestational age
Gender
Surfactant
Singleton v. multiple
Poor weight gain We used average gain per day. More than 15 g per day (not per kg) was considered adequate weight gain. We 
excluded the first 14 days from the calculation in order to compensate for weight loss while feeds were being 
established
Hyperglycaemia A whole-blood glucose level was measured by Accu-Chek® and hyperglycaemia diagnosed if >8.5 mmol/l on 
two consecutive occasions (the monitoring is routinely done 3-hourly)
Severe apnoea No spontaneous breathing >20 seconds, associated with desaturation or bradycardia requiring more 
intervention than stimulation alone (temporary manual ventilation by NeopuffTM or the addition of doxapram)
Duration of O2 therapy Days spent on NCPAP or nasal prong oxygen even if the blender was set at delivering an FiO2 of 0.21 
Sepsis Any positive culture from a normally sterile site
Fungal infection As diagnosed with positive blood culture
NEC Modified Bell’s criteria stage 216 or more
IVH/PVH According to the Papile grading system
Blood transfusion All babies who received packed red blood cells, regardless of number of transfusions or volume of blood transfused
PDA Diagnosed either by ultrasound or strong clinical suspicion and when the PDA was considered 
haemodynamically significant enough to be treated with ibuprofen
BPD Supplemental oxygen dependent at 36-week PMA with chest X-ray changes typical of BPD
Postnatal steroids Any type of steroid for any duration and at any chronological age
TPN Any duration
ROP = retinopathy of prematurity; PET/PIH = pregnancy-induced toxaemia/pregnancy-induced hypertension; BP = blood pressure; HIV = human immunodeficiency virus; DM = diabetes 
mellitus; NCPAP = nasal continuous positive airway pressure; FiO2 = fraction of inspired oxygen; NEC = necrotising enterocolitis; IVH/PVH = intraventricular/periventricular haemorrhage; PDA = patent ductus arteriosus; BPD = bronchopulmonary dysplasia; PMA = postmenstrual age; TPN = total parenteral nutrition.
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On univariate analysis of ‘no ROP’ versus 
‘any ROP’, the smaller, less mature babies, 
as well as those who developed sepsis, 
were at highest risk of developing ROP. In 
comparing CSROP with non-significant ROP 
on univariate analysis, the smaller, less mature 
babies and those with severe apnoea were 
worse affected.
That total parenteral nutrition (TPN) 
was associated with an increased prevalence 
of CSROP was unexpected. Good nutrition 
and growth has been shown to decrease 
the odds of developing ROP.12 However, 
counter-intuitive findings have been 
reported previously.13 We postulate that 
our findings might be biased due to the 
use of average weight gain over the entire 
admission period, as opposed to observing 
shorter periods of impaired growth. These 
factors may affect retinal development. We 
further postulate that the use of TPN may 
have selected out the babies with severe 
disease, because routine TPN is not offered 
at TCH. We did not include duration of 
TPN, which may have been an indicator of 
severity of disease.
Taking all confounding factors into 
consideration on MLR, an inverse 
relationship between birth weight and 
ROP existed. In this study 122 babies 
weighing >1 000 g were screened, of 
whom 19 (5.5%) had ROP. Only two 
babies had CSROP, and they were in the 
group weighing 1 000 - 1 249 g. No babies 
with a BW ≥1  250 g had CSROP. Severe 
apnoea independently raised the risk for 
ROP, but this variable is not easy to define 
in clinical practice.
Postnatal weight gain, in addition to 
BW, has been shown to be important in 
the development of ROP. The WINROP® 
algorithm12 (conceptualised in Sweden), 
based on weekly weight gain, predicts the 
likelihood of a patient developing ROP. 
The first validation studies were published 
in 2009, and since then the algorithm has 
also been tested in developing countries 
such as Brazil.
Strengths and limitations
All infants were screened, or their screening 
supervised, by one ophthalmologist. Our lost-
to-follow-up rate was low compared with other 
SA studies (with the exception of the Chris 
Hani Baragwanath Hospital study).1,6,9,10 The 
exclusion of infants ventilated in the first week of 
life was a limitation. The inclusion of premature 
babies for ROP screening ‘as per consultant 
discretion’ is weakly defined and subjective. 
Table 2. General population characteristics
Birth weight (g)
Characteristic 500 - 750 751 - 1 000 1 001 - 1 250 >1 250 Total
Number of infants, n 41 188 115 12 356
Birth weight (g), median 690 899 1 084 1 310 950
Gestational age (weeks), mean (±SD) 27.8 (±1.5) 28.1 (±1.6) 28.6 (±1.7) 29.7 (±1.3) 28.3 (±1.7)
PDA, % 4.8 19.4 10.7 1.41 36.3
BPD, % 1.1 3.1 2.0 0.8 7.1
IVH/PVH grade 1+2, % 4.8 13.5 10.1 0.6 28.9
IVH/PVH grade 3+4, % 1.1 2.8 0.8 0.3 5.1
SD = standard deviation; PDA = patent ductus arteriosus; BPD = bronchopulmonary dysplasia; IVH/PVH = intraventricular/periventricular haemorrhage.
Table 3. Prevalence of ROP 
Birth weight (g)
Total500 - 750 751 - 1 000 1 001 - 1 250 >1 250 
All ROP, n (%) 11 (3.2) 45 (13.1) 18 (5.2) 1 (0.3) 75 (21.8)
CSROP, n (%) 4 (1.2) 9 (2.6) 2 (0.6) 0 15 (4.4)
Not CSROP, n (%) 7 (2.0) 36 (10.5) 16 (4.6) 1 (0.3) 60 (17.4)
No ROP, n (%) 30 (8.7) 136 (39.5) 93 (27.0) 10 (2.9) 269 (78.2)
ROP = retinopathy of prematurity; CSROP = clinically significant ROP (that is likely to threaten sight).
Fig. 3. Infants screened for ROP, and excluded from and included in the study.
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The reliability of GA estimation varies significantly, depending on how it 
was calculated. In this study the definitions of sepsis and fungaemia were 
very strict, and this may have masked the true influence of mild sepsis or 
fungaemia on ROP.
We did not assess the role of head growth in the development 
of stage 3 ROP at the postmenstrual age of 31 weeks,14 because 
this measurement was inadequately recorded in our study 
population.
Conclusion
The prevalence of ROP and CSROP was low in this cohort of 
preterm infants treated exclusively with non-invasive ventilation 
in the first week of life, when compared with Gilbert et al.’s results.8
Screening for ROP is expensive, time-consuming and potentially 
harmful. SA public health services have limited capacity to adhere 
to the relatively liberal First-World inclusion criteria for screening.
BW is a practical and reproducible variable and can be used in 
ROP screening criteria. No infants in our study group who weighed 
more than 1 250 g had CSROP. The implication is that, in selected 
units, this represents an acceptable upper limit beyond which 
screening is likely to be unnecessary.
Investigation of the applicability of the WINROP® algorithm in 
SA is likely to be the next step towards determining effective ROP 
detection and screening strategies.
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Table 4. Univariate analysis (CSROP v. no ROP and 
insignificant ROP)
Variable CSROP
No ROP plus 
insignificant 
ROP p-value
TPN, n (%) 7 (46.7) 43 (13.1) 0.0003
Severe apnoea, n (%) 10 (66.7) 87 (26.5) 0.0007
Gestational age, mean (±SD) 27.3 (±3.1) 28.4 (±1.8) 0.0209
Poor weight gain, n (%) 8 (53.3) 86 (26.2) 0.0213
Birth weight (g), 
mean (±SD) 851 (±230.5) 949.3 (±177.6) 0.0233
Hyperglycaemia, n (%) 11 (73.3) 145 (44.2) 0.0267
Total oxygen time (days),
mean (±SD) 25.7 (±34.2) 16.3 (±20.9) 0.0664
NCPAP time (days),
mean (±SD) 12.3 (±20.5) 8.0 (±9.6) 0.0770
Any grade IVH/PVH, 
n (%) 8 (53.3) 109 (39.1) 0.1069
Surfactant, n (%) 7 (50.0) 110 (33.5) 0.2035
Ventilation (days), 
mean (±SD)* 2.7 (±11.4) 1.0 (±5.9) 0.2392
Nasal prong oxygen duration 
(days), mean (±SD) 10.7 (±15.4) 7.3 (±12.2) 0.2454
Singleton, n (%) 11 (73.3) 277 (84.2) 0.2651
BPD, n (%) 0 (0) 24 (7.0) 0.2765
NEC, n (%) 0 (0) 24 (7.3) 0.2773
Fungaemia, n (%) 1 (6.7) 9 (2.7) 0.3755
Maternal age (years), 
mean (±SD) 28.6 (±11.4) 27.08 (±7.1) 0.3838
Blood transfusion, n (%) 11 (73.3) 209 (63.5) 0.4391
Sepsis, n (%) 7 (46.7) 128 (38.9) 0.5472
Maternal DM, n (%) 0 (0) 6 (1.9) 0.6051
Small for gestational age,
n (%) 4 (26.7) 108 (32.8) 0.6185
Antenatal steroids, n (%) 11 (73.3) 256 (78.5) 0.6332
HIV-exposed, n (%) 2 (13.3) 56 (17.1) 0.7055
Gender (male), n (%) 7 (46.7) 167 (50.8) 0.7565
PDA, n (%) 6 (40.0) 121 (36.9) 0.8073
Postnatal steroids, n (%) 1 (6.7) 26 (7.9) 0.8593
Maternal PIH/PET, n (%) 7 (50.0) 161 (50.3) 0.9817
CSROP = clinically significant retinopathy of prematurity; ROP = retinopathy 
of prematurity; TPN = total parenteral nutrition; SD = standard deviation; 
NCPAP = nasal continuous positive airway pressure; IVH/PVH = intraventricular/
periventricular haemorrhage; BPD = bronchopulmonary dysplasia; NEC = 
necrotising enterocolitis; DM = diabetes mellitus; HIV = human immunodeficiency 
virus; PDA = patent ductus arteriosus; PET/PIH = pregnancy-induced toxaemia/
pregnancy- induced hypertension; RDS = respiratory distress syndrome.
*Ventilation after the first week of life (for reasons other than RDS).
Table 5. Results of multivariate logistic regression analysis 
(no ROP v. any ROP)
Variable p-value OR CI
Severe apnoea 0.0005 2.67 1.54 - 4.63
Decreasing birth weight 0.0382 1.002 1.00 - 1.004
Female gender 0.0751 1.639 0.951 - 2.824
ROP = retinopathy of prematurity; OR = odds ratio; CI = confidence interval.
